<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02187562</url>
  </required_header>
  <id_info>
    <org_study_id>107.255</org_study_id>
    <nct_id>NCT02187562</nct_id>
  </id_info>
  <brief_title>Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females</brief_title>
  <official_title>Effect of Steady State Meloxicam 15 mg/Day on Low Dose Aspirin (100 mg/Day) Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females. An Open, Randomised, Two-way Crossover Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the influence of meloxicam on low dose aspirin
      induced inhibition of platelet aggregation and thromboxane B2, when meloxicam is given before
      aspirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arachidonic acid induced platelet aggregation</measure>
    <time_frame>up to day 11 (treatment 1), up to day 3 (treatment 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collagen-induced Platelet Aggregation</measure>
    <time_frame>up to day 11 (treatment 1), up to day 3 (treatment 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenosine diphosphate (ADP) Induced Platelet Aggregation</measure>
    <time_frame>up to day 11 (treatment 1), up to day 3 (treatment 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Thromboxane B2 production</measure>
    <time_frame>up to day 11 (treatment 1), up to day 3 (treatment 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to day 11 (treatment 1), up to day 3 (treatment 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Screening, 24 hours after the last Aspirin intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>Screening, 24 hours after the last Aspirin intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability on a 4-point scale</measure>
    <time_frame>24 hours after the last Aspirin intake</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Meloxicam/Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meloxicam days 1-10 / Aspirin days 5-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <arm_group_label>Meloxicam/Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Meloxicam/Aspirin</arm_group_label>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects as determined by results of screening

          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and
             local legislation

          -  Age &gt;=18 and &lt;= 60 years

          -  The Body Mass Index (BMI) ≥ 18.5 kg/m2 (square meters) and ≤ 29.9 kg/m2.

          -  Laboratory values within a clinical normal range

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and
             electrocardiogram (ECG)) deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastro-intestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24 hours) (&lt; 1 month prior to administration
             or during the trial)

          -  Use of any drugs, which might influence the results of the trial, in particular
             aspirin containing drugs(&lt; 14 days prior to administration or during the trial)

          -  Participation in another trial with an investigational drug (&lt; 1 months prior to
             administration (at least 10 times the relevant elimination half-life) or during trial)

          -  Having had prescription medication 2 weeks prior to study drug administration or over
             the counter medication 1 week prior to study drug administration (at least 10 times
             the relevant elimination half-life)

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Inability to refrain from smoking on trial days

          -  Alcohol abuse (&gt; 60 grams (g)/day)

          -  Drug abuse

          -  Blood donation or loss &gt; 400 mL (&lt; 1 month prior to administration or during the
             trial)

          -  Excessive physical activities (&lt; 5 days prior to administration or during the trial)

          -  Any ECG value outside of the reference range of clinical relevance including, but not
             limited to QTcB &gt; 480 ms or QRS interval &gt; 110 ms

          -  History of any familial bleeding disorder

          -  History of haemorrhagic diatheses

          -  History of gastrointestinal ulcer, perforation or bleeding

          -  History of bronchial asthma

          -  Inability to comply with dietary regimen of study centre

          -  Inability to comply with investigator's instructions

        For female subjects:

          -  Pregnancy

          -  Positive pregnancy test

          -  No adequate contraception (e.g. sterilisation, intrauterine device (IUP), oral
             contraceptives)

          -  Inability to maintain this adequate contraception during the whole study period

          -  Lactation period

        Ovarian hormone substitution and oral contraception have to be continued during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2014</study_first_submitted>
  <study_first_submitted_qc>July 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

